We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Neue MR-Kontrastmittel in der Leberdiagnostik Erste klinische Ergebnisse mit hepatobiliärem Eovist® (Gadolinium-EOB-DTPA) und RES-spezifischem Resovist® (SH U 555 A).
- Authors
Reimer, P.; Tombach, B.; Daldrup, Heike; Hesse, T.; Sander, G.; Balzer, T.; Shamsi, K.; Berns, T.; Rummeny, E. J.; Peters, P. E.
- Abstract
The purpose of this work is to describe our initial clinical experience (in 66 patients) with Resovist and Eovist, two new liver-specific MR contrast agents. We focus our report on safety aspects, dose finding, and optimization of technical parameters. Both contrast agents were well tolerated and improved the detectability of focal liver lesions. With Resovist, postcontrast MRI may be started as early as 10 min following injection. The dose of 8 μmol Fe/kg bodyweight was sufficient to achieve diagnostic tumor-liver contrast levels. Since Eovist can also be administered as a bolus, dynamic enhance- ment patterns may be studied for tumor characterization as well. Breath-hold T 1-weighted FLASH images were superior to other T 1-weighted techniques with and without fat saturation.
- Publication
Der Radiologe, 1996, Vol 36, Issue 2, p124
- ISSN
0033-832X
- Publication type
Article
- DOI
10.1007/s001170050049